CTRI/2012/09/003018进行中（未招募）2 期
A phase 2b double-masked, randomized, active-controlled, dose-response study assessing the safety and ocular hypotensive efficacy of AR-12286 in patients with elevated intraocular pressure for 3 months - Nil
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 入组人数
- 195
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.18 year of age or greater.
- •2.Diagnosis of open angle glaucoma (OAG) or ocular hypertension (OHT).
- •3.Unmedicated (post-washout) IOP greater than or equal to 24 mm Hg at 2 eligibility visits (0800 hr), 2-7 days apart, and greater than or equal to 22 mm Hg at 1000 and 1600 hrs at the second qualification visit. If only one eye meets the IOP criteria it must be the same eye that met the criteria at all the qualification timepoints.
- •4.Corrected visual acuity in each eye +1.0 logMAR or better by ETDRS in each eye (equivalent to 20/200).
- •5.Able and willing to give signed informed consent and follow study instructions.
排除标准
- •1.Glaucoma: pseudoexfoliation or pigment dispersion component, history of angle closure or narrow angles. Note: Previous laser peripheral iridotomy is NOT acceptable.
- •2.IOP greater than 36 mm Hg
- •3.Current use of more than 1 ocular hypotensive medications (Note: fixed dose combinations are considered multiple medications).
- •4.Known hypersensitivity to any component of the formulation (benzalkonium chloride, etc.), or to topical anesthetics.
- •5.Previous glaucoma intraocular surgery or glaucoma laser procedures in study eye(s).
- •6.Refractive surgery in study eye(s) (e.g., radial keratotomy, PRK, LASIK, etc.).
- •7.Ocular trauma within the past six months, or ocular surgery or laser treatment within the past three months.
- •8.Evidence of ocular infection, inflammation, clinically significant blepharitis or conjunctivitis at baseline (Visit 1), or a history of herpes simplex keratitis
- •9.Ocular medication of any kind within 30 days of Visit 1, with the exception of a) ocular hypotensive medications (which must be washed out according to the provided schedule), b) lid scrubs (which may be used prior to, but not after Visit 1) or c) lubricating drops for dry eye (which may be used throughout the study).
- •10.Clinically significant ocular disease (e.g. uveitis, severe keratoconjunctivitis sicca) which might interfere with the study, including glaucomatous damage so severe that washout of ocular hypotensive medications for one month is not judged safe.
- •11.Central corneal thickness greater than 600 µm.
- •12.Any abnormality preventing reliable applanation tonometry of either eye.
- •13.Clinically significant abnormalities (as determined by the treating physician) in laboratory tests at screening.
- •14.Known hypersensitivity or contraindication to Beta adrenoceptor antagonists including chronic obstructive pulmonary disease or bronchial asthma; abnormally low blood pressure or heart rate; second or third degree heart block or congestive heart failure; severe diabetes).
- •15.Clinically significant systemic disease (e.g., myasthenia gravis, hepatic, renal, endocrine or cardiovascular disorders) which might interfere with the study.
- •16.Participation in any investigational study within the past 30 days.
- •17.Changes of systemic medication that could have a substantial effect on IOP within 30 days prior to screening, or anticipated during the study.
- •18.Due to the current status of the preclinical safety program, women of childbearing potential who are pregnant, nursing, planning a pregnancy, or not using a medically acceptable form of birth control. An adult woman is considered to be of childbearing potential unless she is one year post-menopausal or three months post-surgical sterilization. All females of childbearing potential must have a negative urine pregnancy test result at the screening examination and must not intend to become pregnant during the study.
研究者
相似试验
进行中（未招募）
1 期
A study to evaluate THR-317 and Lucentis® combination treatment for diabetic macular oedemaEUCTR2017-003897-15-GBOxurion NV72
进行中（未招募）
1 期
A study to evaluate THR-317 and Lucentis® combination treatment for diabetic macular oedemaDiabetic macular oedema (DME)MedDRA version: 20.1 Level: LLT Classification code 10057915 Term: Diabetic macular oedema System Organ Class: 100000004853MedDRA version: 20.1 Level: LLT Classification code 10057934 Term: Diabetic macular edema System Organ Class: 100000004853EUCTR2017-003897-15-BEThromboGenics NV72
进行中（未招募）
1 期
A study to evaluate THR-317 and Lucentis® combination treatment for diabetic macular oedemaDiabetic macular oedema (DME)MedDRA version: 20.1 Level: LLT Classification code 10057915 Term: Diabetic macular oedema System Organ Class: 100000004853MedDRA version: 20.1 Level: LLT Classification code 10057934 Term: Diabetic macular edema System Organ Class: 100000004853EUCTR2017-003897-15-FROxurion NV72
进行中（未招募）
1 期
A study to evaluate THR-317 and Lucentis® combination treatment for diabetic macular oedemaDiabetic macular oedema (DME)MedDRA version: 20.1 Level: LLT Classification code 10057915 Term: Diabetic macular oedema System Organ Class: 100000004853MedDRA version: 20.1 Level: LLT Classification code 10057934 Term: Diabetic macular edema System Organ Class: 100000004853EUCTR2017-003897-15-SKOxurion NV72
进行中（未招募）
1 期
A study to evaluate THR-317 and Lucentis® combination treatment for diabetic macular oedemaDiabetic macular oedema (DME)MedDRA version: 20.1 Level: LLT Classification code 10057915 Term: Diabetic macular oedema System Organ Class: 100000004853MedDRA version: 20.1 Level: LLT Classification code 10057934 Term: Diabetic macular edema System Organ Class: 100000004853EUCTR2017-003897-15-DEOxurion NV72